Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

CMA extends investigation timetable
CMA's recent 'remedies' working paper sparked backlash from the vet sector.
It intends to publish its final decision in February 2026.

The Competition and Markets Authority (CMA) has extended its timetable for the market investigation into the supply of veterinary services by six months.

The inquiry group’s new statutory deadline is 22 May 2026, however inquiry chair Martin Coleman has shared aims to reach a final decision in February 2026.

This extension comes after its recent working paper, detailing suggested remedies for the veterinary sector, received widespread backlash from veterinary organisations. The group reports receiving over 500 responses to its consultation, with the majority of these coming from individuals and independent vets.

The CMA says this decision recognises the complexity of the issues raised by the investigation. It is also the result of the ‘extensive number of detailed submissions’ to the suggested remedies, as well as concerns raised by main parties to its profitability working papers. 

In a blog post, Mr Coleman said that the group had received ‘mixed feedback’ from those in the veterinary sector.

He writes that many respondents said they would ‘welcome’ changes to the regulatory system, particularly highlighting the need to regulate non-veterinary owners of veterinary practices. Many responses also noted the importance of transparency, providing it recognised the unpredictability of clinical practice.

However, he adds that submissions highlighted three concerns: practicalities, costs and proportionality, and the impact on business models.

Some of the specific issues concerned the risks related to implementing the remedies, as well as questioning whether the remedies were proportionate to the issues raised. They also considered how changes to the dispensing of medication could impact business models relying on medicine mark-ups.

Mr Coleman says that the ‘volume and strength of feeling’ of the comments highlighted the need for an extension to the timetable.

The CMA inquiry group will now aim to publish a provisional decision in September 2025, with response hearings to follow at the end of October 2025. 

Mr Coleman writes: “This is not a decision we have taken lightly. We understand the value of providing greater certainty to the many stakeholders – not least the vets, nurses, receptionists and other hardworking frontline staff – affected by this work and delivering outcomes as quickly as possible is a key objective for the CMA.

“It is also important that those outcomes are measured, well-targeted and proportionate, and that the process gives a fair hearing to affected parties.”

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.